Wu Yue'E, Zhang Chonglin, Zhen Qing
Department of Respiration, Xuzhou Children's Hospital, Xuzhou, China.
Department of Respiration, Xuzhou Children's Hospital, Xuzhou, China -
Minerva Pediatr. 2018 Apr;70(2):182-184. doi: 10.23736/S0026-4946.16.04635-1. Epub 2016 May 27.
The treatment of pediatric surgery diseases via utilization of aerosol delivery mechanisms is in progress for the betterment of pediatric care. Over the years, aerosol therapy has come to play an integral role in the treatment of pediatric respiratory diseases. Inhaled aerosol agents such as bronchodilators, corticosteroids, antibiotics, and mucolytics are commonly delivered to spontaneously breathing pediatric patients with a tracheostomy. Administering therapeutic inhaled aerosols to pediatric patients is challenging. The pediatric population ranges in age, which means patients with different airway sizes, breathing patterns, and cooperation levels. These patient-related factors impact the deposition of aerosol drugs in the lungs. The present review article will discuss the recent advancements in the delivery mechanisms for aerosol therapy in pediatric patients with respiratory diseases.
利用气雾剂递送机制治疗小儿外科疾病正在取得进展,以改善儿科护理。多年来,气雾剂疗法在小儿呼吸道疾病的治疗中发挥了不可或缺的作用。吸入性气雾剂药物,如支气管扩张剂、皮质类固醇、抗生素和黏液溶解剂,通常用于给有气管造口术的自主呼吸小儿患者。给小儿患者施用治疗性吸入气雾剂具有挑战性。儿科患者年龄范围广,这意味着患者气道大小、呼吸模式和配合程度各不相同。这些与患者相关的因素会影响气雾剂药物在肺部的沉积。本综述文章将讨论小儿呼吸道疾病患者气雾剂治疗递送机制的最新进展。